Rigel Pharmaceuticals (RIGL): Next-Year EPS Estimate 51.66%
As of 2026-06-22, Rigel Pharmaceuticals (RIGL) has a next-year EPS growth estimate of 51.66%.
On 2026-06-21, analyst consensus for RIGL's next-year EPS growth shifted from 38.98% to 51.66% — a positive change of 12.68 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -84.82%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 51.66%
- EPS growth this year
- -84.82%
- EPS next quarter (est)
- $0.13
- Last price
- $34.45
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-22 | 51.66% | -84.82% | $0.13 | $34.45 |
| 2026-06-21 | 51.66% | -84.82% | $0.13 | $32.91 |
| 2026-06-18 | 38.98% | -83.84% | $0.21 | $32.91 |
| 2026-06-17 | 38.98% | -83.84% | $0.21 | $33.37 |
| 2026-06-16 | 38.98% | -83.84% | $0.21 | $32.46 |
| 2026-06-15 | 38.98% | -83.84% | $0.21 | $33.42 |
| 2026-06-14 | 38.98% | -83.84% | $0.21 | $32.85 |
| 2026-06-11 | 38.98% | -83.84% | $0.21 | $32.08 |
| 2026-06-10 | 38.98% | -83.84% | $0.21 | $30.91 |
| 2026-06-09 | 38.98% | -83.84% | $0.21 | $30.72 |
| 2026-06-08 | 38.98% | -83.84% | $0.21 | $30.08 |
| 2026-06-07 | 38.98% | -83.84% | $0.21 | $29.93 |
| 2026-06-04 | 38.98% | -83.84% | $0.21 | $30.25 |
| 2026-06-03 | 38.98% | -83.84% | $0.21 | $30.30 |
| 2026-06-02 | 38.98% | -83.84% | $0.21 | $30.02 |
| 2026-06-01 | 38.98% | -83.84% | $0.21 | $29.86 |
| 2026-05-31 | 38.98% | -83.84% | $0.21 | $30.49 |
| 2026-05-28 | 38.98% | -83.84% | $0.21 | $30.05 |
| 2026-05-27 | 38.98% | -83.84% | $0.21 | $29.48 |
| 2026-05-26 | 38.98% | -83.84% | $0.21 | $29.17 |
| 2026-05-25 | 38.98% | -83.84% | $0.21 | $29.01 |
| 2026-05-24 | 38.98% | -83.84% | $0.21 | $29.01 |
| 2026-05-21 | 38.98% | -83.84% | $0.21 | $29.19 |
| 2026-05-20 | 38.98% | -83.84% | $0.21 | $28.82 |
| 2026-05-19 | 38.98% | -83.84% | $0.21 | $28.30 |
| 2026-05-18 | 38.98% | -83.84% | $0.21 | $28.61 |
| 2026-05-17 | 38.98% | -83.84% | $0.21 | $29.01 |
| 2026-05-14 | 38.98% | -83.84% | $0.21 | $31.92 |
| 2026-05-13 | 38.98% | -83.84% | $0.21 | $32.50 |
Screen Performance
Aggregate stats across all 1803 tickers our top-EPS-revision screen has flagged over the past 82 days.
- Median return since detection
- +3.2%
- % of tickers in the green
- 57%
- Median return on winners
- +19.6%
- Large revisions captured
- 859
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Rigel Pharmaceuticals's next-year EPS growth estimate?▾
As of 2026-06-22, Rigel Pharmaceuticals (RIGL) has a next-year EPS growth estimate of 51.66%, based on analyst consensus.
When was the latest EPS estimate revision for RIGL?▾
The most recent revision occurred on 2026-06-21, when analysts adjusted the next-year EPS growth estimate from 38.98% to 51.66%.
What sector and industry does Rigel Pharmaceuticals belong to?▾
Rigel Pharmaceuticals operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RIGL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rigel Pharmaceuticals (RIGL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports